On June 20, 2025, Amarin Corporation entered into a long-term exclusive license agreement with Recordati, receiving a $25 million upfront and potential milestone payments up to $150 million for developing its product VAZKEPA® in 59 European countries. Additionally, a global restructuring plan aims to cut operating costs by approximately $70 million annually with associated charges estimated between $30 million and $37 million expected by the end of 2025.